From March 25th – 26th Enzyre organised a two day bootcamp in Hotel Ruimzicht (Doetinchem, NL) with our collaborating partners EPR Partner, Micronit, Sencio and Fuse Design Consultants to draw up and refine the design of the biochip. Next steps were made to create a cheap, simple, small and applicable design for point of care disease management with personalized medicine.
Enzyre BV, a company developing a point-of-care platform technology for enzymatic reactions, was founded on May 17, 2016. Dr. Waander van Heerde, an experienced blood coagulation physiologist, and Drs. Guido Maertens, a seasoned biotech entrepreneur, are founders of this highly innovative company with the mission to bring personalized diagnostics to the patient. Personalized diagnostics as Enzyre envisions it will open up the way to true personalized medicine and disease management. The focus will lay on the development of a series of tests for blood coagulation initially.
On April 10, 2017 Enzyre obtained an exclusive license of the Radboudumc to a proprietary technology using chemiluminescence to detect enzymatic reactions using a light sensor chip and enzyme specific substrates. The technology was developed with funding of a PIDON grant by a consortium including NXP Semiconductors and Chiralix. The license agreement includes the option to purchase the patent protecting the technology. Enzyre will use the technology to develop a point-of-care biochip for blood coagulation able to measure multiple enzymatic reaction simultaneously. Together with the execution of the license agreement Radboudumc became a shareholder in Enzyre and invested an undisclosed amount in the development of the biochip.